Eight Sleep, maker of the temperature-controlled Pod smart mattress cover, has raised a new funding round led by Tether Investments that values the company at $1.5 billion, the company announced in 2026. The round is explicitly earmarked to expand Eight Sleep’s ambitions from sleep optimization into what the company calls predictive, AI-driven health — a shift covered by outlets including Refresh Miami and Fitt Insider.
An AI trained on a billion hours of sleep
Eight Sleep says its predictive AI models are now trained on more than one billion hours of real-world sleep data gathered from users across more than 35 countries, one of the larger proprietary sleep datasets in the consumer wearable space. The company has used that dataset to power Autopilot, its flagship feature that automatically adjusts the Pod’s temperature through the night based on a sleeper’s biometric signals, and has since released Autopilot 4.0, which the company describes as an “AI Sleep Agent” that also pulls in daytime activity data from Apple Health to explain sleep quality in the context of a user’s full day, not just the hours in bed.
New features: pregnancy mode and international expansion
In May 2026, Eight Sleep introduced a Pregnancy Mode as a free AI-powered Autopilot feature for members, adjusting temperature regulation to account for the physiological changes of pregnancy. The company also expanded into China in April 2026, calling it the largest single market expansion in its history and a bet that the world’s largest population represents a major growth opportunity for AI-driven sleep tech.
Clinical claims and regulatory ambitions
Eight Sleep has pointed to two peer-reviewed studies as clinical backing for its approach: one found the Pod reduced menopausal hot flashes by 56 percent, and another linked the device’s climate control to improved cardiovascular recovery markers by helping restore a more natural circadian temperature rhythm during sleep. Building on that evidence, the company filed with the FDA in the 2025-2026 window seeking Class II medical device clearance specifically for detecting and mitigating obstructive sleep apnea — a move that would push Eight Sleep from a wellness gadget into a regulated medical device category, similar to the path some smartwatch heart-monitoring features have already taken.
Reasons for caution
A $1.5 billion valuation for a bed-cooling subscription product invites obvious skepticism: Eight Sleep’s Pod carries a hardware cost that can run into the thousands of dollars plus an ongoing monthly subscription, and predictive AI claims about sleep are difficult for outside researchers to independently verify without access to the company’s proprietary dataset. FDA clearance for sleep apnea detection, if it comes through, is not guaranteed, and Class II review processes can take considerably longer than companies initially project.
Eight Sleep’s trajectory also stands out because it began as a niche luxury product — a temperature-controlled mattress topper aimed at biohackers and people with disposable income to spend on marginal sleep gains. The jump to a $1.5 billion valuation and an FDA medical-device filing marks an unusually fast pivot from lifestyle gadget to regulated health product, one that mirrors how Whoop and Oura have each tried to graduate from wellness accessory to something closer to a clinical tool without losing the consumer simplicity that built their user base in the first place.
The China expansion adds another layer of complexity worth watching: entering the world’s largest population as a premium sleep-tech brand means competing against a fast-growing domestic wearable and smart-home industry, while also navigating a different regulatory environment for any future medical-device claims Eight Sleep might pursue there. Success in China would meaningfully expand Eight Sleep’s billion-hour sleep dataset, but it also raises the same data-governance questions that have followed other Western health-tech companies expanding into the market.
What’s next
If Eight Sleep’s FDA filing succeeds, the Pod would become one of the few consumer bedding products with a genuine medical-device designation, potentially opening insurance reimbursement pathways that most sleep-tech products lack. Combined with the China expansion and continued Autopilot upgrades, the company’s strategy for the rest of 2026 is clearly aimed at converting its sleep-data trove into a defensible position in the broader AI health category — one increasingly crowded by Oura’s Health Radar, Whoop’s clinician access, and Samsung’s Vitals scoring, all chasing the same “AI as home health monitor” territory from different hardware angles.
